What's Cooking at Flamel?

Earlier in the week, Flamel Technologies (Nasdaq: FLML  ) updated investors on what to expect for the rest of the year, calling finding partners to help pay for its hepatitis C and diabetes compounds a top priority.

Sales numbers from Flamel's only currently marketed drug, Coreg CR, were already known, after partner GlaxoSmithKline (NYSE: GSK  ) announced the drug's $70 million in first-quarter sales several weeks ago.

The pivotal phase 3 COSMOS study testing Coreg CR with lisinopril for hypertension is expected to be completed this month, but no timeline was given on when the data will be publicly available. Glaxo has said that it plans to submit a label-expanding marketing application to the FDA later in the year. Flamel will hopefully have more data on some of its numerous preclinical-stage projects by the end of the year as well.

Flamel didn't give any guidance on when it might ink a deal for its hepatitis C interferon drug or long-acting diabetes compound, but did call finding partners for these two drugs its highest priorities. Surely Flamel can get some partner to help pay for the costs of developing its hepatitis C drug -- everyone wants a piece of the action after all -- but it remains to be seen how strong a deal and how much upfront cash Flamel can get for these compounds. Let's not forget that Flamel has had multiple partners, including Biovail (NYSE: BVF  ) and Bristol-Myers Squibb (NYSE: BMY  ) , bolt from it in the past.

Flamel has been tightening its belt and cutting costs across the board in the first quarter. It burned through a measly $1.8 million in the quarter, and at that rate its $39 million in cash on the balance sheet will last it for a long time. Hopefully Flamel can add to this cash pile with some positive deals for its pipeline drugs.

Read/Post Comments (0) | Recommend This Article (9)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 646200, ~/Articles/ArticleHandler.aspx, 10/28/2016 5:48:35 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,161.19 -8.49 -0.05%
S&P 500 2,126.41 -6.63 -0.31%
NASD 5,190.10 -25.87 -0.50%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/28/2016 4:00 PM
FLML $10.91 Down +0.00 +0.00%
Flamel Technologie… CAPS Rating: ***
BMY $51.00 Down -0.96 -1.85%
Bristol-Myers Squi… CAPS Rating: ****
BVF.DL $0.00 Down +0.00 +0.00%
Biovail Corp (USA) CAPS Rating: ***
GSK $40.14 Down -0.28 -0.69%
GlaxoSmithKline CAPS Rating: ***